Dose Escalation With Infliximab Biosimilar Can Restore Responses in IBD

(MedPage Today) -- LAS VEGAS -- In patients with inflammatory bowel disease who lost response after infliximab (Remicade) induction, escalating the maintenance dose of the subcutaneous infliximab biosimilar CT-P13 improved clinical response and...
Source: MedPage Today Gastroenterology - Category: Gastroenterology Source Type: news